CN119173528A - 针对cd277和肿瘤抗原的双特异性抗体 - Google Patents
针对cd277和肿瘤抗原的双特异性抗体 Download PDFInfo
- Publication number
- CN119173528A CN119173528A CN202380030646.1A CN202380030646A CN119173528A CN 119173528 A CN119173528 A CN 119173528A CN 202380030646 A CN202380030646 A CN 202380030646A CN 119173528 A CN119173528 A CN 119173528A
- Authority
- CN
- China
- Prior art keywords
- seq
- cdrl1
- cdrl2
- cdrl3
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159045 | 2022-02-27 | ||
| EP22159045 | 2022-02-27 | ||
| EP22162761 | 2022-03-17 | ||
| EP22162761 | 2022-03-17 | ||
| EP23157433 | 2023-02-19 | ||
| EP23157433 | 2023-02-19 | ||
| PCT/EP2023/054762 WO2023161457A1 (en) | 2022-02-27 | 2023-02-26 | Bispecific antibodies against cd277 and a tumor-antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119173528A true CN119173528A (zh) | 2024-12-20 |
Family
ID=85382872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380030646.1A Pending CN119173528A (zh) | 2022-02-27 | 2023-02-26 | 针对cd277和肿瘤抗原的双特异性抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250163157A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482859A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508867A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240149438A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119173528A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243624A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314678A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010485A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023161457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025532758A (ja) | 2022-10-04 | 2025-10-03 | イムチェック セラピューティクス エスエーエス | 癌の治療における使用のためのbtn3a活性化抗体、bcl2阻害剤及び低メチル化剤の併用 |
| JP2026506893A (ja) | 2023-02-23 | 2026-02-27 | イムチェック セラピューティクス エスエーエス | Btn3a活性化抗体と免役チェックポイント阻害剤の併用 |
| TW202506731A (zh) | 2023-04-27 | 2025-02-16 | 法商感應檢查療法公司 | 治療多重抗藥性細菌感染之方法 |
| WO2024261239A1 (en) | 2023-06-23 | 2024-12-26 | Imcheck Therapeutics | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| US20120064096A1 (en) | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| US20150353643A1 (en) | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP4177273A1 (en) | 2013-02-20 | 2023-05-10 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| WO2017055388A2 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| KR102491752B1 (ko) | 2016-08-29 | 2023-01-26 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스 |
| EP3773676A4 (en) | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| PL3830119T3 (pl) | 2018-08-01 | 2026-05-25 | Imcheck Therapeutics | Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| US12441789B2 (en) | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AR122656A1 (es) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | Anticuerpos que se unen a cd3 / folr1 |
-
2023
- 2023-02-26 IL IL314678A patent/IL314678A/en unknown
- 2023-02-26 KR KR1020247031819A patent/KR20240149438A/ko active Pending
- 2023-02-26 JP JP2024550555A patent/JP2025508867A/ja active Pending
- 2023-02-26 CA CA3243624A patent/CA3243624A1/en active Pending
- 2023-02-26 CN CN202380030646.1A patent/CN119173528A/zh active Pending
- 2023-02-26 WO PCT/EP2023/054762 patent/WO2023161457A1/en not_active Ceased
- 2023-02-26 US US18/841,269 patent/US20250163157A1/en active Pending
- 2023-02-26 EP EP23707379.6A patent/EP4482859A1/en active Pending
-
2024
- 2024-08-26 MX MX2024010485A patent/MX2024010485A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314678A (en) | 2024-10-01 |
| JP2025508867A (ja) | 2025-04-10 |
| KR20240149438A (ko) | 2024-10-14 |
| WO2023161457A1 (en) | 2023-08-31 |
| EP4482859A1 (en) | 2025-01-01 |
| CA3243624A1 (en) | 2023-08-31 |
| MX2024010485A (es) | 2024-12-06 |
| US20250163157A1 (en) | 2025-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI830151B (zh) | 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 | |
| CN113480656B (zh) | 抗ror1抗体 | |
| CN114728065A (zh) | 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 | |
| US20250163157A1 (en) | Bispecific antibodies against cd277 and a tumor-antigen | |
| TW201936638A (zh) | 雙特異性異質二聚體雙功能抗體及彼等之用途 | |
| JP2022548947A (ja) | Ceacam5およびcd3に対する二特異性抗体 | |
| JP7851303B2 (ja) | ヒトcd3イプシロンに結合する新規なヒト抗体 | |
| KR20220111308A (ko) | 인간화 cldn18.2 항체 | |
| EP4421093A1 (en) | Antigen-binding protein comprising two fc domains and use thereof | |
| EP4663662A1 (en) | Trispecific antigen-binding molecule and use thereof | |
| CN106831996A (zh) | 新型双特异性抗体及其用途 | |
| US10633458B2 (en) | Cell engaging binding molecules | |
| CN116891530A (zh) | 双特异性抗体及其应用 | |
| JP2024507937A (ja) | Cd123及びガンマデルタt細胞受容体に結合する抗体 | |
| JP2025524347A (ja) | ガンマデルタt細胞受容体に結合するバリアント抗体 | |
| TW202535960A (zh) | 抗體及其藥物偶聯物和用途 | |
| EP4454706A1 (en) | Novel egfr binding proteins | |
| CN120858119A (zh) | 抗muc17、cd3和cd28三特异性抗体 | |
| CA3281557A1 (en) | Trispecific antigen-binding molecule and use thereof | |
| HK40061499A (en) | Anti-ror1 antibodies | |
| EA051514B1 (ru) | Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3 | |
| HK40067877A (en) | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |